Date: 2012-09-13
Type of information: R&D agreement
Compound: Nanocyclix® technology
Company: Oncodesign (France) Sanofi (France)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
licensing
Action mechanism: Nanocyclix® is a proprietary medicinal chemistry technology and research platform based on macrocyclisation chemical methodology and knowledge that gives access to potent and selective kinase inhibitors based on shape complementarity in the ATP binding site of kinases. In this way, unprecedented selectivity is achieved even among kinases with high homology. In addition, the technology allows rapid improvement in the pharmacokinetic properties of the Nanocyclix® leads based on established knowledge.
Disease:
Details: Oncodesign, a drug discovery company and oncology pharmacology service provider, has entered into a strategic research collaboration with Sanofi to apply exclusively Oncodesign’s Nanocyclix® technology to several Sanofi kinase target programs. The application of Nanocyclix® to Sanofi’s kinase lead programs aims to allow for a quicker selection of development candidates for multiple undisclosed kinase targets in kinase families that are notoriously difficult to address. Under the terms of the agreement, Oncodesign will exclusively apply its Nanocyclix® technology platform in multiple undisclosed Sanofi kinase programs for a number of therapeutic applications over a period of four years.
Financial terms: Oncodesign is entitled to a technology access fee and discovery, development, regulatory and commercial milestone payments totaling up to €130 million and low single digit royalties on net sales.
Latest news:
